Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma
NCT00362570 is a phase 2 interventional trial sponsored by Ohio State University Comprehensive Cancer Center. As of 21 Nov 2026, it is completed. It studies Temozolomide in Anaplastic Oligodendroglioma and Oligoastrocytoma, Mixed. The registry lists an enrollment of 1 participant at 1 site in 1 country. The registry lists a start date of 31 May 2005 and a primary completion date of 30 Apr 2007.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00362570 |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Ohio State University Comprehensive Cancer Center |
| Enrollment | 1 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Anaplastic Oligodendroglioma and Oligoastrocytoma, Mixed |
| Drugs | Temozolomide |
| Start | 31 May 2005 |
| Primary completion | 30 Apr 2007 |
| Study completion | 31 Mar 2011 |
| Last update posted | 30 Nov 2017 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Herbert Newton, MD
Ohio State University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ohio State University
Columbus
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00362570
Each answer restates registry values shown on this page.
What is NCT00362570?
NCT00362570 is a phase 2 interventional trial sponsored by Ohio State University Comprehensive Cancer Center. It studies Temozolomide in Anaplastic Oligodendroglioma and Oligoastrocytoma, Mixed.
Who leads NCT00362570?
The registry names Herbert Newton, MD (principal investigator, Ohio State University) as the overall official.
Where does NCT00362570 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00362570 study?
The registered drug and biological interventions are Temozolomide.
When did NCT00362570 end?
The registry lists a primary completion date of 30 Apr 2007 and a study completion date of 31 Mar 2011. The sponsor last updated the record on 30 Nov 2017.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.